Patents by Inventor Ana Martin-Villalba

Ana Martin-Villalba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
    Patent number: 9850308
    Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: December 26, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAETSKLINIKUM HEIDELBERG
    Inventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
  • NEUTRALIZATION OF CD95 ACTIVITY BLOCKS INVASION OF GLIOBLASTOMA CELLS IN VIVO
    Publication number: 20160115236
    Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
    Type: Application
    Filed: April 30, 2015
    Publication date: April 28, 2016
    Applicants: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts, Universitaetsklinikum Heidelberg
    Inventors: Ana MARTIN-VILLALBA, Susanne KLEBER, Benedikt WIESTLER, Peter G. KRAMMER, Christel HEROLD-MENDE, Ignacio SANCHO-MARTINEZ
  • Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
    Patent number: 9309320
    Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: April 12, 2016
    Assignees: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Universitaetsklinikum Heidelberg
    Inventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
  • Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro
    Publication number: 20110300113
    Abstract: The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.
    Type: Application
    Filed: September 19, 2007
    Publication date: December 8, 2011
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Ana Martin-Villalba, Nina Corsini, Elisabeth Letellier, Susanne Kleber, Stefan Klussmann
  • USE OF CD95 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20110189194
    Abstract: The present invention refers to the use of an inhibitor of the CD95/CD95L system for the prevention and/or treatment of an inflammatory disorder or for the prevention and/or treatment of an inflammatory process in a neuronal disorder, particularly in a CNS disorder.
    Type: Application
    Filed: July 14, 2009
    Publication date: August 4, 2011
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Ana Martin-Villalba, Elisabeth Letellier, Ignacio Sancho-Martinez
  • Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
    Patent number: 7935339
    Abstract: The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: May 3, 2011
    Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Ana Martin-Villalba, Peter Krammer, Deana Demjen
  • Neutralization of CD95 Activity Blocks Invasion of glioblastoma Cells In Vivo
    Publication number: 20100322922
    Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
    Type: Application
    Filed: December 28, 2007
    Publication date: December 23, 2010
    Applicants: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts, Universitaetsklinikum Heidelberg
    Inventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
  • Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries
    Publication number: 20060234968
    Abstract: The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
    Type: Application
    Filed: February 10, 2004
    Publication date: October 19, 2006
    Inventors: Ana Martin-Villalba, Peter Krammer, Deana Demjen
  • Gd3-synthesis inhibitors for treating neuropathological disorders
    Publication number: 20040092438
    Abstract: The present invention relates to the use of GD3 synthase inhibitors for treating neuropathological disorders, in particular cerebral ischemia, traumatic damage to the brain and spinal cord, and neurodegenerative disorders, and signs, symptoms and dysfunctions associated therewith, and to a method for the preparation of pharmaceuticals for the treatment of neuropathological disorders.
    Type: Application
    Filed: July 12, 2002
    Publication date: May 13, 2004
    Inventors: Ana Martin-Villalba, Johannes Schenkel, Susanne Kleber, Roberto Testi
  • Combination of compounds that inhibit the biological effects of tnf-alpha and cd95l in a medicament
    Publication number: 20030082180
    Abstract: The invention relates to medicaments which contain one or more compounds inhibiting the biological effects of TNF-&agr; and CD95L, e.g. by blocking the binding of these ligands to their natural receptors thus eliminating signal transduction. These compounds are preferably a neutralizing anti-TNF-&agr; antibody and a neutralizing anti-CD95L antibody. The invention also relates to the use of the above compounds for preventing or treating an apoplectic stroke or heart attack.
    Type: Application
    Filed: September 16, 2002
    Publication date: May 1, 2003
    Inventors: Peter Krammer, Ana Martin-Villalba